Literature DB >> 21106883

Identification of ligand-selective peptide antagonists of the mineralocorticoid receptor using phage display.

Jun Yang1, Ching-yi Chang, Rachid Safi, James Morgan, Donald P McDonnell, Peter J Fuller, Colin D Clyne, Morag J Young.   

Abstract

The mineralocorticoid receptor (MR) is a member of the nuclear receptor superfamily. Pathological activation of the MR causes cardiac fibrosis and heart failure, but clinical use of MR antagonists is limited by the renal side effect of hyperkalemia. The glucocorticoid cortisol binds the MR with equivalent affinity to that of the mineralocorticoids aldosterone and deoxycorticosterone. In nonepithelial tissues, including the myocardium, which do not express the cortisol-inactivating enzyme 11β hydroxysteroid dehydrogenase 2, cortisol has been implicated in the activation of MR. The mechanisms for ligand- and tissue-specific actions of the MR are undefined. Over the past decade, it has become clear that coregulator proteins are critical for nuclear receptor-mediated gene expression. A subset of these coregulators may confer specificity to MR-mediated responses. To evaluate whether different physiological ligands can induce distinct MR conformations that underlie differential coregulator recruitment and ligand-specific gene regulation, we utilized phage display technology to screen 10(8) 19mer peptides for their interaction with the MR in the presence of agonist ligands. We identified ligand-selective MR-interacting peptides that acted as potent antagonists of MR-mediated transactivation. This represents a novel mechanism of MR antagonism that may be manipulated in the rational design of a ligand- or tissue-selective MR modulator to treat diseases like heart failure without side effects such as hyperkalemia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21106883      PMCID: PMC5417296          DOI: 10.1210/me.2010-0193

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  64 in total

1.  Development of peptide antagonists that target estrogen receptor beta-coactivator interactions.

Authors:  J M Hall; C Y Chang; D P McDonnell
Journal:  Mol Endocrinol       Date:  2000-12

Review 2.  Aldosterone and the heart.

Authors:  M Young; J W Funder
Journal:  Trends Endocrinol Metab       Date:  2000-08       Impact factor: 12.015

Review 3.  Aldosterone: its receptor, target genes, and actions.

Authors:  David Pearce; Aditi Bhargava; Timothy J Cole
Journal:  Vitam Horm       Date:  2003       Impact factor: 3.421

4.  Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors.

Authors:  J W Funder; P T Pearce; R Smith; J Campbell
Journal:  Endocrinology       Date:  1989-10       Impact factor: 4.736

5.  A signature motif in transcriptional co-activators mediates binding to nuclear receptors.

Authors:  D M Heery; E Kalkhoven; S Hoare; M G Parker
Journal:  Nature       Date:  1997-06-12       Impact factor: 49.962

6.  Coactivation of liver receptor homologue-1 by peroxisome proliferator-activated receptor gamma coactivator-1alpha on aromatase promoter II and its inhibition by activated retinoid X receptor suggest a novel target for breast-specific antiestrogen therapy.

Authors:  Rachid Safi; Agnes Kovacic; Stéphanie Gaillard; Yoko Murata; Evan R Simpson; Donald P McDonnell; Colin D Clyne
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

7.  The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding.

Authors:  P H Giangrande; E A Kimbrel; D P Edwards; D P McDonnell
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

Review 8.  The mineralocorticoid receptor and its coregulators.

Authors:  Jun Yang; Morag J Young
Journal:  J Mol Endocrinol       Date:  2009-08       Impact factor: 5.098

9.  The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11 beta-hydroxysteroid dehydrogenase.

Authors:  M Lombes; S Kenouch; A Souque; N Farman; M E Rafestin-Oblin
Journal:  Endocrinology       Date:  1994-09       Impact factor: 4.736

10.  Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure.

Authors:  Wenning Qin; Amy E Rudolph; Brian R Bond; Ricardo Rocha; Eric A G Blomme; Joseph J Goellner; John W Funder; Ellen G McMahon
Journal:  Circ Res       Date:  2003-06-05       Impact factor: 17.367

View more
  9 in total

Review 1.  Allosteric modulators of steroid hormone receptors: structural dynamics and gene regulation.

Authors:  Raj Kumar; Iain J McEwan
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

2.  Diverse immunostaining patterns of mineralocorticoid receptor monoclonal antibodies.

Authors:  Celso E Gomez-Sanchez; Mary Warden; Miriam T Gomez-Sanchez; Xu Hou; Elise P Gomez-Sanchez
Journal:  Steroids       Date:  2011-09-10       Impact factor: 2.668

Review 3.  The multifaceted mineralocorticoid receptor.

Authors:  Elise Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Compr Physiol       Date:  2014-07       Impact factor: 9.090

Review 4.  Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?

Authors:  Elise P Gomez-Sanchez
Journal:  J Cardiovasc Pharmacol       Date:  2016-01       Impact factor: 3.105

5.  The 2010 Philip S. Portoghese Medicinal Chemistry Lectureship: addressing the "core issue" in the design of estrogen receptor ligands.

Authors:  John A Katzenellenbogen
Journal:  J Med Chem       Date:  2011-07-11       Impact factor: 7.446

Review 6.  Central regulation of blood pressure by the mineralocorticoid receptor.

Authors:  Elise P Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Mol Cell Endocrinol       Date:  2011-06-01       Impact factor: 4.102

Review 7.  Mineralocorticoid receptor antagonists for cardioprotection in chronic kidney disease: a step into the future.

Authors:  Maria-Eleni Alexandrou; Marieta P Theodorakopoulou; Mehmet Kanbay; Pantelis A Sarafidis
Journal:  J Hum Hypertens       Date:  2022-01-04       Impact factor: 2.877

Review 8.  Genomic and rapid effects of aldosterone: what we know and do not know thus far.

Authors:  Milla Marques Hermidorff; Leonardo Vinícius Monteiro de Assis; Mauro César Isoldi
Journal:  Heart Fail Rev       Date:  2017-01       Impact factor: 4.214

9.  Use of phage display to identify novel mineralocorticoid receptor-interacting proteins.

Authors:  Jun Yang; Peter J Fuller; James Morgan; Hirotaka Shibata; Donald P McDonnell; Colin D Clyne; Morag J Young
Journal:  Mol Endocrinol       Date:  2014-07-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.